This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .


Post-Test - Peak Issues (Issue 3): Clinical Use Of Incretin-Based Therapies To Treat Type 2 Diabetes


INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.



1. Which one of the following statements regarding GLP-1 is true?
A: GLP-1 is rendered inactive by DPP-4
B: GLP-1 receptor agonists are susceptible to breakdown by DPP-4
C: Native GLP-1 has a half-life on the order of hours
D: GLP-1 acts by binding to an intestinal receptor

2. Which of the following statements regarding the incretin effect is false?
A: In healthy individuals, circulatory GLP-1 and GIP levels rise after a meal
B: The incretin effect is blunted in diabetes
C: Incretin hormones have diverse effects throughout the body
D: The incretin system primarily regulates second-phase insulin response

3. Which of the following statements regarding the effects of GLP-1 is false?
A: GLP-1 delays gastric emptying
B: GLP-1 promotes weight loss
C: GLP-1 infusions can trigger a sense of fullness and premature satiety
D: GLP-1 suppresses the secretion of glucagon from the pancreas in a glucose-independent manner

4. Which of the following agents is deemed a short-acting GLP-1 receptor agonist?
A: Albiglutide
B: Exenatide LAR
C: Liraglutide
D: Lixisenatide
E: Taspoglutide

5. Which of the following statements regarding the CV effects of GLP-1 receptor agonists is true?
A: Exenatide, liraglutide, and exenatide LAR all reduce systolic blood pressure (BP)
B: GLP-1 agonists tend to increase diastolic BP
C: Only long-acting GLP-1 receptor agonists decrease triglycerides
D: All GLP-1 receptor agonists increase HDL cholesterol

6. Which of the following adverse effects is not commonly associated with GLP-1 receptor agonist therapy?
A: Nausea
B: Vomiting
C: Diarrhea
D: CV events

7. The FDA recommends which course of action for patients who have symptoms of acute pancreatitis?
A: Continue with GLP-1 receptor agonist therapy, but monitor symptoms carefully
B: Reduce dose of GLP-1 receptor agonist therapy, and monitor symptoms carefully
C: Discontinue until the patient recovers, then reinitiate at half the previous dose
D: Discontinue GLP-1 receptor agonist therapy promptly and do not readminister

8. According to the ADA/EASD guidelines, GLP-1 receptor agonists are currently recommended for which of the following?
A: As monotherapy when exercise and diet are no longer effective
B: As adjunctive therapy to other oral agents when intensification of control is required or weight gain is a concern
C: As an alternative to insulin therapy for patients with an A1C level > 10%
D: GLP-1 receptor agonists are not currently recommended in the ADA/EASD guidelines

9. GLP-1 receptor agonists sometimes cause antibody formation. This is likely related to what?
A: Duration of dosing
B: Particular agent used (higher homology with native GLP-1 results in fewer antibodies)
C: Route of administration
D: Progression of T2DM (irrespective of particular agent used)

10. Which of the following agents has the greatest effect on PPG when administered as monotherapy?
A: Exenatide
B: Liraglutide
C: Lixisenatide
D: They have equal effects

Return to Activity